The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2022

Filed:

Dec. 01, 2017
Applicant:

Ohio University, Athens, OH (US);

Inventors:

John J. Kopchick, Athens, OH (US);

Reetobrata Basu, Athens, OH (US);

Assignee:

Ohio University, Athens, OH (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/27 (2006.01); C12N 15/113 (2010.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 31/337 (2006.01); A61K 31/352 (2006.01); A61K 31/437 (2006.01); A61K 31/704 (2006.01); C07K 16/28 (2006.01); A61K 31/713 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1138 (2013.01); A61K 31/337 (2013.01); A61K 31/352 (2013.01); A61K 31/437 (2013.01); A61K 31/704 (2013.01); A61K 31/713 (2013.01); A61K 33/243 (2019.01); A61K 38/27 (2013.01); A61K 47/60 (2017.08); A61P 35/00 (2018.01); C07K 16/2869 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01);
Abstract

Various aspects of the present invention relate to a method of treating cancer in a subject having cancer cells, wherein the cancer cells possess at least one growth hormone receptor, and wherein the method includes controlling an action of the growth hormone receptor. In various non-limiting embodiments, controlling an action of the growth hormone receptor may occur via knock down of the growth hormone receptor, or may be caused by inhibiting growth hormone action, such as via the use of antibodies directed against growth hormone or the growth hormone receptor. Methods may also relate to administering an antagonist of the growth hormone receptor, and administering at least one anti-tumor drug in concert with administration of the antagonist. Another aspect may include a method of maintaining an anti-tumor drug in cancer cells of a subject by controlling an action of at least one growth hormone receptor in the cancer cells.


Find Patent Forward Citations

Loading…